Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including
amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and
feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS
patients.